703P - Survival of Hispanic germ cell tumor patients at a single academic institution vs. SEER

Background

Incidence of testicular germ cell tumors (TGCTs) is rising in Hispanic Whites (HW), who tend to be younger than non-Hispanic White (NHW) patients at diagnosis and have poorer survival, as shown in SEER. The detailed prognostic and biofeature information needed to understand these disparities is not adequately assessed in large population-based registries. We initiated an investigation of a primarily Hispanic clinical cohort at the University of Southern California (USC).

Methods

For TGCT patients in SEER18 in 2000-2011 and within subgroups of seminomas (SGCT) or non-seminomas (NSGCT), we determined 5-year absolute survival by actuarial methods, cumulative expected values calculated by Ederer II procedure, implemented in SEER*Stat. For consecutive patients at USC, we estimated 5-year survival as a proportion of patients still alive at <5 years, calculating 95%CI by the Wilson score interval method with continuity correction, implemented in R.

Results

In both the SEER18 and USC cohorts, HWs with TGCT had lower 5-year survival than NHWs (see table). HWs with NSGCTs (n=84) had tumors that included the following elements: 50% teratoma, 10% choriocarcinoma, 15% embryonal, 2% yolk sac, and 8% somatic differentiation. At diagnosis, three patients (2%) had non-pulmonary visceral metastases, and 37 (27%) and 21 (16%) had regional and nonregional nodal metastases, respectively. Among HWs with NSGCTs, 57% were classified as good risk, 20% intermediate, 20% poor risk and 3% unknown. Of the 49 HWs with SGCT, 94% were classified as good risk, 2% as intermediate risk, and 4% were unknown. Table: 703P

5-year survival

Conclusions

In our clinical population of TGCT patients, HWs had worse 5-year outcomes than NHWs, consistent with SEER findings. In this limited series of HWs, poor risk disease appears to be more frequent than in historic series of NHWs. A larger representative series is needed to more fully understand this outcomes disparity and define poor risk features in this population.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

D.I. Quinn: Financial Interests, Personal, Other, Employment and Stockholder: AbbVie. All other authors have declared no conflicts of interest.